Ciphergen, Bio-Rad, GenTel, NIH

Premium

Ciphergen to Sell Proteomics Tools Arm to Bio-Rad as Q2 Revenues Fall 24 Percent
 
Bio-Rad this week said it plans to acquire Ciphergen’s proteomic business for $20 million and buy a $ 3-million stake in the company [See related story].
 
Ciphergen announced the sale as it reported that second-quarter revenues dropped 24 percent to $5.3 million from $6.9 million during the year-ago period.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb or 360Dx Premium member?
Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.